JP2008512088A - ＩＧＦＲ経路のモディファイヤーとしてのＧＡＬＮＴｓおよび使用方法 - Google Patents

ＩＧＦＲ経路のモディファイヤーとしてのＧＡＬＮＴｓおよび使用方法 Download PDF

Info

Publication number
JP2008512088A
JP2008512088A JP2007518149A JP2007518149A JP2008512088A JP 2008512088 A JP2008512088 A JP 2008512088A JP 2007518149 A JP2007518149 A JP 2007518149A JP 2007518149 A JP2007518149 A JP 2007518149A JP 2008512088 A JP2008512088 A JP 2008512088A
Authority
JP
Japan
Prior art keywords
galnt
assay
igfr
cell
assay system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007518149A
Other languages
English (en)
Japanese (ja)
Inventor
ロリ， エス． フリードマン，
ヘレン フランシス−ラング，
アネット， エル． パークス，
ケネス， ジェームス ショー，
ティモシー， エス． ホイヤー，
リン マーガレット ビヤーク，
Original Assignee
エクセリクシス， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクセリクシス， インク． filed Critical エクセリクシス， インク．
Publication of JP2008512088A publication Critical patent/JP2008512088A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11002—Procollagen-proline dioxygenase (1.14.11.2), i.e. proline-hydroxylase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
JP2007518149A 2004-06-21 2005-06-20 ＩＧＦＲ経路のモディファイヤーとしてのＧＡＬＮＴｓおよび使用方法 Pending JP2008512088A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58169604P 2004-06-21 2004-06-21
PCT/US2005/021622 WO2006009928A2 (en) 2004-06-21 2005-06-20 Galnts as modifiers of the igfr pathway and methods of use

Publications (1)

Publication Number Publication Date
JP2008512088A true JP2008512088A (ja) 2008-04-24

Family

ID=35785569

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007518149A Pending JP2008512088A (ja) 2004-06-21 2005-06-20 ＩＧＦＲ経路のモディファイヤーとしてのＧＡＬＮＴｓおよび使用方法
JP2007518148A Withdrawn JP2008511287A (ja) 2004-06-21 2005-06-20 ＩＧＦＲ経路のモディファイヤーとしてのＰＦＫｓおよび使用方法
JP2007518155A Pending JP2008503238A (ja) 2004-06-21 2005-06-20 ＩＧＦＲ経路のモディファイヤーとしてのＰ４ＨＡｓおよび使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007518148A Withdrawn JP2008511287A (ja) 2004-06-21 2005-06-20 ＩＧＦＲ経路のモディファイヤーとしてのＰＦＫｓおよび使用方法
JP2007518155A Pending JP2008503238A (ja) 2004-06-21 2005-06-20 ＩＧＦＲ経路のモディファイヤーとしてのＰ４ＨＡｓおよび使用方法

Country Status (7)

Country Link
US (4) US20090142272A1 (en17)
EP (3) EP1759006B1 (en17)
JP (3) JP2008512088A (en17)
AT (1) ATE536549T1 (en17)
AU (3) AU2005265186A1 (en17)
CA (3) CA2571250A1 (en17)
WO (3) WO2006009928A2 (en17)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2465852A1 (en) * 2003-08-18 2012-06-20 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
EP2227542A1 (en) * 2007-12-17 2010-09-15 Novartis AG Altering high density lipoprotein levels through udp-n-acetyl-alpha-d-galactosamine:polypeptide n-acetlgalactosaminyltransferase (galnt) modulation
JP2015505959A (ja) * 2011-12-05 2015-02-26 ネステク ソシエテ アノニム 癌を有する患者に治療を選択する方法
US10219473B2 (en) * 2016-10-13 2019-03-05 Seminis Vegetable Seeds, Inc. Spinach hybrid SVVB3719 and parents thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068868A2 (en) 2000-03-15 2001-09-20 Fibrogen, Inc. Alpha(iii) subunit of prolyl 4-hydroxylase
AU2001258234A1 (en) * 2000-05-11 2001-11-20 Glycozym Aps Methods of modulating functions of polypeptide galnac-transferases and of screening substances therefor, pharmaceutical compositions comprising such agents
CA2438215A1 (en) * 2001-02-09 2002-08-22 Incyte Genomics, Inc. Putative human enzymes
WO2002088363A2 (en) 2001-05-02 2002-11-07 Bayer Healthcare Ag Regulation of novel human prolyl 4-hydroxylases
EP1506286B1 (en) 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
DE60314658D1 (de) * 2002-11-08 2007-08-09 Glycozym Aps Verfahren zur identifizierung von die funktionen von polypeptid-galnac-transferasen modulierenden agentien, solche agentien umfassende pharmazeutische zusammensetzungen und verwendung solcher agentien zur herstellung von arzneimitteln
JP2007527235A (ja) * 2004-01-28 2007-09-27 エクセリクシス， インク． ＩＧＦＲ経路のモディファイヤーとしてのＩＴＰＫｓおよび使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6010071242, 安達雄哉, "ヒト胃癌細胞株におけるＮ−ａｃｅｔｙｌｇａｌａｃｔｏｓａｍｉｎｙｌｔｒａｎｓｆｅｒａｓｅのアンチセンス抑制によるＮＫおよびＬＡＫ細胞", 札幌医学雑誌, 1996, 第６５巻，第６号, ｐ．５２１−５３１ *
JPN6010071243, Ｒｅｃｅｎｔ ｐｒｏｇｒｅｓｓ ｉｎ ｈｏｒｍｏｎｅ ｒｅｓｅａｒｃｈ． ２００３， Ｖｏｌ．５８， ｐ．３２５−３４２ *
JPN6010071244, Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ ｂｉｏｌｏｇｉｃａｌ ｃｈｅｍｉｓｔｒｙ． １９９７， Ｖｏｌ．２７２， Ｎｏ．３８， ｐ．２３５０３−２３５１４ *

Also Published As

Publication number Publication date
JP2008511287A (ja) 2008-04-17
EP1758993A4 (en) 2008-02-27
US7888048B2 (en) 2011-02-15
WO2006009952A1 (en) 2006-01-26
JP2008503238A (ja) 2008-02-07
EP1758993A2 (en) 2007-03-07
AU2005265190B2 (en) 2011-05-19
CA2567982A1 (en) 2006-01-26
CA2568331A1 (en) 2006-01-26
EP1759207A4 (en) 2008-02-27
AU2005265186A1 (en) 2006-01-26
ATE536549T1 (de) 2011-12-15
AU2005265214A1 (en) 2006-01-26
US20090028844A1 (en) 2009-01-29
US20130212716A1 (en) 2013-08-15
CA2571250A1 (en) 2006-01-26
WO2006009924A2 (en) 2006-01-26
EP1759006A2 (en) 2007-03-07
US20090025096A1 (en) 2009-01-22
US20090142272A1 (en) 2009-06-04
WO2006009928A2 (en) 2006-01-26
WO2006009928A3 (en) 2006-11-09
WO2006009924A3 (en) 2007-03-01
AU2005265190A1 (en) 2006-01-26
EP1759006B1 (en) 2011-12-07
EP1759006A4 (en) 2007-10-31
EP1759207A1 (en) 2007-03-07

Similar Documents

Publication Publication Date Title
US20130212716A1 (en) PFKs as Modifiers of the IGFR Pathway and Methods of Use
US7927872B2 (en) ALDOs as modifiers of the IGF pathway and methods of use
US7785805B2 (en) MAN2As as modifiers of the IGFR pathway and methods of use
US7888047B2 (en) PDEs as modifiers of the IGFR pathways and methods of use
JP2008503241A (ja) ＰＴＥＮ経路のモディファイヤーとしてのＰＧＤｓおよび使用方法
JP2008513015A (ja) Ｒａｃ経路のモディファイヤーとしてのｐｉｋ４ｃａおよび使用方法
JP2008546409A (ja) Ａｘｉｎ経路のモディファイヤーとしてのＧＦＡＴ及び使用方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110616

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111122